In January 2023, elacestrant (as ORSERDUTM, Stemline Therapeutics, Menarini Group, Florence, Italy) received FDA approval for the treatment of adult patients ER-positive/HER2-negative ESR1-mutated advanced or metastatic BC (developments summarized recently by [253]). Here, ESR1 is linked to breast cancer.